We conducted a double-blinded, placebo-controlled clinical trial to explore how myo-inositol (MI) influences insulin resistance (IR) among obese individuals with non-alcoholic fatty liver disease (NAFLD). Our study involved 48 participants who were randomly assigned to receive either 4 grams of MI or a placebo daily for eight weeks.
Throughout this period, we measured various parameters such as weight, serum glucose levels, and insulin sensitivity indices before and after the intervention. Notably, we found that MI supplementation led to significant improvements in the expression levels of key genes related to the AMPK/PI3K/AKT signaling pathway, which plays a crucial role in regulating metabolism.
The results indicated noteworthy enhancements in insulin resistance for those who received MI, measured through multiple indices, reinforcing its potential benefits for liver health management. Thus, we observed that supplementing with myo-inositol not only bolstered the expression of important metabolic genes but also helped improve insulin resistance in our participants with NAFLD.
Read More
7
Myo-Inositol shows promise for NAFLD
Does myo-inositol supplementation influence oxidative stress biomarkers in patients with non-alcoholic fatty liver disease?
We aimed to explore the effects of myo-inositol (MI) supplementation on oxidative stress in obese patients suffering from non-alcoholic fatty liver disease (NAFLD). In our double-blinded, placebo-controlled study, 51 newly diagnosed patients were divided into two groups—one receiving 4 grams of MI daily and the other receiving a placebo—while following dietary recommendations for an 8-week period.
At the end of the trial, we observed that both groups experienced significant reductions in body weight and other obesity measures. Interestingly, those taking MI showed a slightly larger decrease in weight, which was statistically significant. While there was no significant difference in most antioxidant levels between the two groups, we noted that the MI group did see a greater reduction in serum nitric oxide.
Although both groups benefited in some ways—like a decrease in feelings of hunger and desire for unhealthy foods—the MI group specifically showed a more pronounced reduction in the desire to eat fatty foods. Overall, MI supplementation positively influenced weight and certain oxidative stress markers, while also providing potential advantages in managing dietary cravings. However, we did not find significant changes in many of the oxidative stress biomarkers related to liver function, emphasizing that while MI appears beneficial for some aspects, more research is needed to fully understand its effects on liver health.
Read More
Most Useful Reviews
9
Liver cleanse effective
15 people found this helpful
I took it after my friend recommended it to cleanse the liver.
Read More
9
Liver cleanse effective
13 people found this helpful
I took it after my friend recommended it to cleanse the liver.
Read More
9
Liver cleanse effective
4 people found this helpful
I took it after my friend recommended it to cleanse the liver.
We conducted a double-blinded, placebo-controlled clinical trial to explore how myo-inositol (MI) influences insulin resistance (IR) among obese individuals with non-alcoholic fatty liver disease (NAFLD). Our study involved 48 participants who were randomly assigned to receive either 4 grams of MI or a placebo daily for eight weeks.
Throughout this period, we measured various parameters such as weight, serum glucose levels, and insulin sensitivity indices before and after the intervention. Notably, we found that MI supplementation led to significant improvements in the expression levels of key genes related to the AMPK/PI3K/AKT signaling pathway, which plays a crucial role in regulating metabolism.
The results indicated noteworthy enhancements in insulin resistance for those who received MI, measured through multiple indices, reinforcing its potential benefits for liver health management. Thus, we observed that supplementing with myo-inositol not only bolstered the expression of important metabolic genes but also helped improve insulin resistance in our participants with NAFLD.
Read More
7
Myo-Inositol shows promise for NAFLD
Does myo-inositol supplementation influence oxidative stress biomarkers in patients with non-alcoholic fatty liver disease?
We aimed to explore the effects of myo-inositol (MI) supplementation on oxidative stress in obese patients suffering from non-alcoholic fatty liver disease (NAFLD). In our double-blinded, placebo-controlled study, 51 newly diagnosed patients were divided into two groups—one receiving 4 grams of MI daily and the other receiving a placebo—while following dietary recommendations for an 8-week period.
At the end of the trial, we observed that both groups experienced significant reductions in body weight and other obesity measures. Interestingly, those taking MI showed a slightly larger decrease in weight, which was statistically significant. While there was no significant difference in most antioxidant levels between the two groups, we noted that the MI group did see a greater reduction in serum nitric oxide.
Although both groups benefited in some ways—like a decrease in feelings of hunger and desire for unhealthy foods—the MI group specifically showed a more pronounced reduction in the desire to eat fatty foods. Overall, MI supplementation positively influenced weight and certain oxidative stress markers, while also providing potential advantages in managing dietary cravings. However, we did not find significant changes in many of the oxidative stress biomarkers related to liver function, emphasizing that while MI appears beneficial for some aspects, more research is needed to fully understand its effects on liver health.
Read More
User Reviews
USERS' SCORE
Good
Based on 9 Reviews
8.5
All Reviews
Positive Reviews
Negative Reviews
9
Liver cleanse effective
15 people found this helpful
I took it after my friend recommended it to cleanse the liver.
Read More
9
Liver cleanse effective
13 people found this helpful
I took it after my friend recommended it to cleanse the liver.
Read More
9
Liver cleanse effective
4 people found this helpful
I took it after my friend recommended it to cleanse the liver.
Read More
9
Liver cleanse effective
2 people found this helpful
I took it after my friend recommended it to cleanse the liver.
Read More
9
Liver cleanse effective
I took it after my friend recommended it to cleanse the liver.
Liver disease encompasses a variety of conditions that affect the liver's ability to function effectively. The liver is a vital organ responsible for many important tasks, including metabolizing nutrients, detoxifying harmful substances, and producing bile for digestion. Common forms of liver disease include hepatitis, fatty liver disease, cirrhosis, and liver cancer. Each of these conditions can significantly impact liver function and overall health, leading to symptoms that range from fatigue and jaundice to more serious complications requiring urgent medical attention.
The causes of liver disease are diverse and can include chronic alcohol abuse, viral infections, autoimmune disorders, and metabolic conditions like obesity and diabetes. Early detection is key to managing liver disease effectively, often involving lifestyle changes, medications, and sometimes surgical interventions. Regular check-ups and liver function tests are recommended for individuals at higher risk, such as those with a family history of liver disease or those who lead certain lifestyle habits. Adopting a balanced diet and reducing alcohol intake can greatly aid in liver health and help prevent the onset of these conditions.
Inositol is a naturally occurring sugar alcohol that plays a crucial role in cellular signaling and the structural integrity of cell membranes. It is a member of the B-vitamin complex and exists in several forms, with myo-inositol being the most prevalent in the human body. Inositol is found in various foods, including fruits, beans, grains, and nuts, and it can also be synthesized by the body from glucose. It is often marketed as a supplement for various health benefits, including mental health support, particularly for conditions like anxiety and depression, and is studied for its potential role in managing polycystic ovary syndrome (PCOS).
Research suggests that inositol may help in alleviating symptoms associated with these health issues by enhancing insulin sensitivity and regulating hormonal balance. While it is generally considered safe for consumption, individuals should consult with healthcare professionals before starting any new supplement regimen, especially if they have existing health conditions or are taking other medications. As with any supplement, the effectiveness can vary from person to person, and understanding the underlying scientific evidence can guide informed choices.
Myo-inositol (MI) supplementation has shown promise in addressing aspects of liver health, particularly in individuals with non-alcoholic fatty liver disease (NAFLD). A double-blinded, placebo-controlled clinical trial involving 48 obese participants revealed that MI significantly improved insulin resistance, a crucial factor in liver metabolism regulation. The study highlighted enhancements in the expression of metabolic genes associated with the AMPK/PI3K/AKT signaling pathway, indicating that MI could be beneficial for managing liver health in NAFLD patients [1].
Additionally, another study focusing on oxidative stress in NAFLD patients found that while MI supplementation did lead to a greater reduction in certain markers compared to the placebo group, the overall impact on liver function-related oxidative stress biomarkers was not as pronounced. Participants taking MI reported benefits such as reduced cravings for unhealthy foods, suggesting potential positive effects on dietary habits, but further research is needed to completely understand its implications for liver health [2]. Overall, the current evidence suggests that myo-inositol may support liver health management, yet additional studies are warranted to solidify its efficacy.
The optimal dose of myo-inositol for treating liver disease, specifically non-alcoholic fatty liver disease (NAFLD), appears to be 4 grams daily. This was established through two separate double-blinded, placebo-controlled clinical trials, wherein participants who took this specific dosage experienced significant improvements in insulin resistance and metabolic parameters compared to those on a placebo [1][2].
Both studies indicated that the supplementation led to favorable outcomes, including better expressions of metabolic genes and notable weight loss effects. While myo-inositol supplementation did improve certain factors related to liver health, including oxidative stress markers, further research is still necessary to fully delineate its comprehensive effects on liver function [1][2]. Therefore, if you are considering myo-inositol for liver disease management, a daily intake of 4 grams may be the optimal starting point to discuss with your healthcare provider.
8
Myo-inositol improves insulin resistance
The effect of myo-inositol supplementation on AMPK/PI3K/AKT pathway and insulin resistance in patients with NAFLD.
We conducted a double-blinded, placebo-controlled clinical trial to explore how myo-inositol (MI) influences insulin resistance (IR) among obese individuals with non-alcoholic fatty liver disease (NAFLD). Our study involved 48 participants who were randomly assigned to receive either 4 grams of MI or a placebo daily for eight weeks.
Throughout this period, we measured various parameters such as weight, serum glucose levels, and insulin sensitivity indices before and after the intervention. Notably, we found that MI supplementation led to significant improvements in the expression levels of key genes related to the AMPK/PI3K/AKT signaling pathway, which plays a crucial role in regulating metabolism.
The results indicated noteworthy enhancements in insulin resistance for those who received MI, measured through multiple indices, reinforcing its potential benefits for liver health management. Thus, we observed that supplementing with myo-inositol not only bolstered the expression of important metabolic genes but also helped improve insulin resistance in our participants with NAFLD.
7
Myo-Inositol shows promise for NAFLD
Does myo-inositol supplementation influence oxidative stress biomarkers in patients with non-alcoholic fatty liver disease?
We aimed to explore the effects of myo-inositol (MI) supplementation on oxidative stress in obese patients suffering from non-alcoholic fatty liver disease (NAFLD). In our double-blinded, placebo-controlled study, 51 newly diagnosed patients were divided into two groups—one receiving 4 grams of MI daily and the other receiving a placebo—while following dietary recommendations for an 8-week period.
At the end of the trial, we observed that both groups experienced significant reductions in body weight and other obesity measures. Interestingly, those taking MI showed a slightly larger decrease in weight, which was statistically significant. While there was no significant difference in most antioxidant levels between the two groups, we noted that the MI group did see a greater reduction in serum nitric oxide.
Although both groups benefited in some ways—like a decrease in feelings of hunger and desire for unhealthy foods—the MI group specifically showed a more pronounced reduction in the desire to eat fatty foods. Overall, MI supplementation positively influenced weight and certain oxidative stress markers, while also providing potential advantages in managing dietary cravings. However, we did not find significant changes in many of the oxidative stress biomarkers related to liver function, emphasizing that while MI appears beneficial for some aspects, more research is needed to fully understand its effects on liver health.
References
Aghajani T, Arefhosseini S, Ebrahimi-Mameghani M, Safaralizadeh R. The effect of myo-inositol supplementation on AMPK/PI3K/AKT pathway and insulin resistance in patients with NAFLD. Food Sci Nutr. 2024;12:7177. 10.1002/fsn3.4267
Rostami S, Arefhosseini S, Tutunchi H, Khoshbaten M, Ebrahimi-Mameghani M. Does myo-inositol supplementation influence oxidative stress biomarkers in patients with non-alcoholic fatty liver disease?. Food Sci Nutr. 2024;12:1279. 10.1002/fsn3.3842